Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / B Group, Inc.
Form 13F · Q2 2026

B Group, Inc.

CIK 2043476Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$213M
Reported book value
19
Positions
7
Quarters on record
Top 50
Positions

B Group, Inc. — holdings

Top 18 positions of 19, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1ADMA Adma Biologics Inc3.3M+1.7%$27M12.8%
2PALI Palisade Bio Inc11.4M+0.0%$24M11.2%
3NRXP Nrx Pharmaceuticals Inc4.1M+36.4%$17M7.9%
4FTH Faeth Therapeutics Inc610,169—$15M7.2%
5TSHA Taysha Gene Therapies Inc1.8M+0.0%$12M5.8%
6PRAX Praxis Precision Medicines I33,237+0.0%$11M5.2%
7CLLS Cellectis S A3.3M+0.0%$10M4.6%
8ZLAB Zai Lab Ltd450,646+0.0%$9M4.0%
9GPCR Structure Therapeutics Inc140,000+9.8%$8M3.5%
10ORKA Oruka Therapeutics Inc75,000+0.0%$7M3.4%
11IOVA Iovance Biotherapeutics Inc1.5M+0.0%$6M2.9%
12SYRE Spyre Therapeutics Inc70,000−30.0%$6M2.9%
13AURA Aura Biosciences Inc764,243+27.9%$5M2.5%
14ASMB Assembly Biosciences Inc175,706+0.0%$5M2.3%
15DRUG Bright Minds Biosciences Inc67,500+0.0%$5M2.2%
16RARE Ultragenyx Pharmaceutical In135,000+0.0%$5M2.1%
17SGHT Sight Sciences Inc970,000+0.0%$4M1.7%
18FHTX Foghorn Therapeutics Inc200,000+96.1%$976,0000.5%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.